This phenomenon was not observed in patients with wild-type EGFR. While the reason for these results was unclear, tumor volume reduction by resection of the primary site and EGFR-TKI treatment could synergize patient prognosis with EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is neoplasm.